Fig. 1
STEAP3 is involved in FAC-mediated antiviral effects. (A) siControl or siSTEAP3-transfected RD cells were infected with EV-A71 (MOI = 10−3) with or without FAC (100 µM) for 24 h. The CPE was visualized using bright-field microscopy. Scale bar = 100 μm. (B) The total cell lysate was extracted from siRNA-transfected RD cells infected with EV-A71 (MOI = 10−3) for 24 h, resolved by SDS-PAGE, and then analyzed by immunoblotting with the indicated antibodies. The uncropped and unprocessed blots are provided in Supplementary Fig. S16. (C) The virus titer was measured from siRNA-transfected RD cells infected with EV-A71 (MOI = 10−3) in the presence or absence of FAC for 12 and 24 h. *p < 0.05 versus siControl-transfected cells without FAC treatment. #p < 0.05 compared to siControl-transfected cells with FAC treatment using the student’s t-test. All data are shown as the mean (± s.d.). (D) Caco-2 cells expressing siRNA targeting to control or STEAP3 were infected with SARS-CoV-2 S entry virus for 24 h with or without FAC treatment. The total cell lysate was collected, and the luciferase activity was measured.
